XML 16 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 4,644 $ 4,237
Marketable Securities, Current 2,478 2,113
Receivables 5,922 5,543
Inventories 1,250 1,241
Prepaid expenses and other 754 570
Total Current Assets 15,048 13,704
Property, plant and equipment 5,014 4,980
Goodwill 6,865 6,875
Other intangible assets 1,213 1,385
Deferred income taxes 2,346 2,996
Marketable Securities, Noncurrent 2,526 2,719
Other assets 965 1,048
Total Assets 33,977 33,707
Current Liabilities:    
Short-term debt obligations 1,461 992
Accounts payable 1,699 1,664
Accrued liabilities 5,418 5,271
Deferred income 647 762
Income taxes payable 213 152
Total Current Liabilities 9,438 8,841
Deferred income 492 547
Income taxes payable 996 973
Pension and other liabilities 1,155 1,283
Long-term debt 6,982 5,716
Total Liabilities 19,063 17,360
Commitments and contingencies (Note 17)
Bristol-Myers Squibb Company Shareholders' Equity:    
Preferred stock 0 0
Common stock 221 221
Capital in excess of par value of stock 1,845 1,725
Accumulated other comprehensive loss (2,421) (2,503)
Retained earnings 34,141 33,513
Less cost of treasury stock (19,003) (16,779)
Total Bristol-Myers Squibb Company Shareholders' Equity 14,783 16,177
Noncontrolling interest 131 170
Total Equity 14,914 16,347
Total Liabilities and Equity $ 33,977 $ 33,707